Denali Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4DN.MU | B9A.F | IONS | SRPT | MAZE | PTCT | |
|---|---|---|---|---|---|---|
| Market cap | 2.92B | 2.45B | 6.67B | 2.01B | 1.85B | 5.76B |
| P/E (TTM) | — | 250.7 | — | — | — | — |
| Forward P/E | — | — | -35.0 | 7.8 | -10.5 | 28.4 |
| Price/book | 3.2 | 1.2 | 15.1 | 1.3 | 4.1 | -30.1 |
| Dividend yield | — | 0.68% | — | — | — | — |
| 1-year change | +29.14% | +13.08% | −45.82% | +7.65% | +6.54% | −5.09% |
| Today | +4.91% | −0.29% | −0.67% | +2.43% | +3.50% | +1.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 4DN.MU news ›Denali Therapeutics Q3 2026 Earnings Preview
Denali Therapeutics reports Q3 earnings Tuesday after the close. - Denali Therapeutics (DNLI) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, after market close. - The consensus EPS estimate is -$0.37, and the…
Denali Therapeutics (DNLI) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Denali Therapeutics today and set a price target of $29.00. According to TipRanks, Fye is a 5-star analyst with an average return of 9.6% and a 55.50% success rate. Fye covers the…
Stifel Nicolaus Remains a Buy on Denali Therapeutics (DNLI)
In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on Denali Therapeutics, with a price target of $41.00. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA…
Denali Therapeutics price target raised to $34 from $31 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $31 and keeps an Outperform rating on the shares. The firm update... Denali Therapeutics price target raised to $34 from $31 at Baird Baird raised the firm’s…
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head Contrast
Posted by Mitch Edgeman on Oct 19th, 2026 Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Century Therapeutics (NASDAQ:IPSC – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the…
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Denali Therapeutics (DNLI) to $40 from $36 and keeps an Overweight rating o... Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley Morgan Stanley…
Denali Therapeutics price target raised to $35 from $30 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $30 and keeps a Buy rating on the share... Denali Therapeutics price target raised to $35 from $30 at B. Riley B. Riley analyst Mayank…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- seekingalpha.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.